Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 46.15%. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.52 per share when it actually produced a loss of $0.52, delivering no surprise.Over the last four quarters, the company has sur ...

Financial Performance - For the three months ended September 30, 2024, net sales were $96.7 million, compared to $78.0 million for the same period in 2023, representing a 23.3% increase[108]. - The company incurred net losses of $21.4 million for the three months ended September 30, 2024, compared to a net loss of $30.4 million for the same period in 2023, indicating a 29.5% improvement[107]. - Net sales for Q3 2024 were $96.7 million, a 24% increase from $78.0 million in Q3 2023[146]. - The net loss for Q3 2024 was $21.4 million, a 30% improvement from a net loss of $30.4 million in Q3 2023[148]. - Net sales for the nine months ended September 30, 2024, were $278.0 million, a 20% increase from $232.3 million for the same period in 2023[162]. - The net loss for the nine months ended September 30, 2024, was $112.8 million, compared to a net loss of $97.9 million in the same period of 2023, reflecting a 15% increase[190]. Cost and Expenses - Operating expenses increased to $98.7 million for the three months ended September 30, 2024, compared to $87.5 million for the same period in 2023, reflecting a 12.9% rise[108]. - Cost of sales increased to $22.6 million in Q3 2024 from $18.5 million in Q3 2023, aligning with the increase in net sales[152]. - SG&A expenses rose to $64.0 million in Q3 2024, an increase of 18% from $54.2 million in Q3 2023[153]. - R&D expenses for Q3 2024 were $34.7 million, up from $33.3 million in Q3 2023, with core R&D expenses at $22.3 million[155]. - Selling, general, and administrative expenses grew by 19% to $192.2 million, primarily due to increased compensation and discretionary expenses[169][170]. - Research and development expenses decreased to $99.9 million from $101.7 million, influenced by a one-time payment related to the iDose TR NDA[171]. - Non-operating expenses surged to $18.2 million, a 163% increase from $6.9 million, largely due to expenses from a Convertible Note exchange[175]. Sales and Market Performance - U.S. glaucoma product sales increased by 35% to $51.6 million in Q3 2024, driven by the introduction of iDose TR and higher demand for the iStent family[147]. - International sales of glaucoma products rose by 21% to $24.5 million in Q3 2024, reflecting growth in key international markets[148]. - U.S. net sales of glaucoma products increased by 30%, reaching $143.3 million compared to $112.8 million in the prior year[163]. - International sales of glaucoma products rose by 19%, totaling $75.8 million, driven by growth in key markets despite unfavorable foreign exchange rates[164]. Margins and Financial Ratios - Gross margin for the three months ended September 30, 2024, was 77%, slightly up from 76% in the same period of 2023[108]. - Gross margin improved to 77% in Q3 2024, compared to 76% in Q3 2023[152]. - Cost of sales increased to $65.4 million, reflecting a 15% rise from $56.7 million, maintaining a gross margin of 76%[166]. Cash Flow and Liquidity - Cash and cash equivalents totaled approximately $100.1 million as of September 30, 2024, up from $93.5 million at the end of 2023[183]. - The company had net working capital of $325.6 million, indicating sufficient current assets to cover short-term liabilities[186]. - For the nine months ended September 30, 2024, net cash from investing activities was $36.0 million, compared to $27.0 million for the same period in 2023, reflecting an increase of approximately 33.3%[196]. - Cash received from stock option exercises and employee stock purchases was $36.9 million in 2024, compared to $12.9 million in 2023, marking an increase of approximately 185.3%[196]. - Financing activities provided $31.4 million of net cash in the nine months ended September 30, 2024, significantly higher than $7.7 million in 2023, representing an increase of approximately 308.9%[196]. Strategic Developments - The company received FDA approval for the iDose TR in December 2023 and began commercialization in February 2024, aiming to enhance treatment options for glaucoma[105]. - The company acquired a clinical-stage biopharma company for $5.0 million in stock and $5.1 million in cash, with potential milestone payments of up to $201.0 million[115]. - A new government tiered rebate structure was negotiated with France's CEPS, expected to reduce rebate accrual rates in 2024 compared to historical levels[114]. - The company closed a transaction to exchange $230.0 million in Convertible Senior Notes for 4,253,423 shares of common stock, reducing the balance of Convertible Notes by $226.7 million[110]. Risks and Future Outlook - Supply chain challenges and inflationary pressures have led to increased costs for certain components and raw materials, which may continue throughout 2024[123]. - The company expects capital expenditures to be modestly lower for the remainder of 2024 as expansion activities related to manufacturing facilities wind down[196]. - The company believes that cash from operating, financing, and investing activities will be sufficient to meet ongoing operations and liquidity requirements for at least the next 12 months[198]. - There have been no significant changes to material cash requirements as of September 30, 2024, compared to disclosures in the Annual Report for the year ended December 31, 2023[198]. - There have been no material changes in exposure to market risk since December 31, 2023[203]. - The company has no off-balance sheet arrangements[197]. - There have been no material changes to critical accounting policies and significant estimates during the three and nine months ended September 30, 2024[202].

Glaukos (GKOS) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on November 4. ...

Glaukos Corporation (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry's 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $7.1 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 3 ...

Glaukos (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 63.5% compared with 9.1% growth of the industry. The S&P 500 composite has risen 17.4% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is focused on the ...

For the quarter ended June 2024, Glaukos (GKOS) reported revenue of $95.69 million, up 19% over the same period last year. EPS came in at -$0.52, compared to -$0.55 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $88.41 million, representing a surprise of +8.24%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.52. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

Glaukos Corporation (GKOS) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter's adjusted loss of 55 cents per share. The GAAP loss per share was $1.06 compared with the prior-year quarter's reported loss of 68 cents. Revenue Details Glaukos registered revenues of $95.7 million in the second quarter, up 19% year over year on a reported basis and 20% at constant currency (cc). The figure also surpassed ...

Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.58 per share when it actually produced a loss of $0.70, delivering a surprise of -20.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Glaukos, which belongs t ...

Glaukos (GKOS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on July 31. On the ...